In February 2025, the MTP Council announced national evaluations of two technologies within the Orderly introduction framework in Sweden. The Council commissioned the Dental and Pharmaceutical Benefits Agency (TLV) to perform a health economic evaluation of rectal spacers (SpaceOAR Hydrogel and Barrigel) used during radiotherapy in prostate cancer (re-evaluation) and AI-based solution (Stratipath Breast) for breast cancer risk assessment.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Fassbender et al. examined how digital therapeutics (DTx) are being adopted across various European countries, exploring variations in regulatory pathways, reimbursement policies, and clinical validation requirements. The study emphasized the importance of co-design, ecosystem-driven approaches, and policy harmonization to facilitate broader adoption and sustainable integration of DTx into European healthcare systems. The authors proposed a structured framework to enhance DTx accessibility and adoption across European healthcare landscapes.

On February 4, 2025, the French National Authority for Health (HAS) published its 2025-2030 strategic project. The document outlines current challenges and opportunities in the health system, defines three strategic priorities, and identifies three key areas in which HAS intends to increase its investment over the next five years.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of the 24th of February, we plan to work on 15 projects. Review the complete list of planned activities in this post.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Volker S. examined the 2022 EU HTA regulation and its activities, including Joint Clinical Assessment, Joint Scientific Consultations, and Horizon Scanning. While the regulation aims to harmonize clinical data assessments and reduce duplication, concerns persist about increased bureaucracy and delays in market access. The study highlighted the potential threats and opportunities for manufacturers and national affiliates, offering insights into the evolving European HTA landscape.

In January 2025, the National Institute for Health and Care Research (NIHR) in England released two Med Tech-related assessments in its HTA Journal, which concerned a clinical decision support tool for lower urinary tract symptom in men and multi-cancer early detection tests for general population screening. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs NICE guidance.

In February 2025, the Board of Danish Regions meeting was held. The key themes discussed concerned prioritizing public wellbeing and environmental sustainability, expanding cancer treatment capacity and funding, and the status of the Common Regional Procurement Strategy 2020-2025 (including “green” procurement).

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Value-based Publications Digest. In a recent publication, Vogler et al. proposed fit-for-purpose policy recommendations based on the analysis of current funding and pricing structures for point-of-care tests (POCTs) for community-acquired acute respiratory tract infections across Europe. The authors aimed to improve antibiotic prescribing for respiratory infections by enhancing the uptake of POCTs. The study suggested several funding policy and pricing-related recommendations ‒ such as physician-focused remuneration models, public reimbursement coverage, and strategic procurement approaches ‒ which can substantially boost the implementation of rapid diagnostic tools in outpatient settings.

In February 2025, seven health apps reached Level 3+ of the mHealthBelgium validation pyramid, meaning regular reimbursement. These apps can only be reimbursed within the specific care pathway “Remote monitoring and therapeutic guidance in chronic heart failure”.

On February 7, 2025, the National Institute for Health and Care Excellence (NICE) published a manual for a new HealthTech program and launched a consultation. The HealthTech program will produce two types of guidance: Interventional Procedures guidance and HealthTech guidance (replacing former Medical Technologies guidance and Diagnostics guidance). The deadline for comments submission is March 6, 2025.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, Haluza et al. conducted an exploratory survey at the General Hospital in Vienna, Austria, to assess anesthesia team members’ perspectives on precycling and recycling of anesthetic gases. The study revealed a generally positive attitude toward adopting sustainable practices, suggesting a strong potential for reducing volatile anesthetic use through active staff engagement.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, Cocco et al. applied early economic modeling to establish target product profile specifications based on cost-effectiveness considerations, helping developers define key test performance criteria. The authors used the example of a novel rapid diagnostic for Clostridioides difficile infection in the UK setting. The study underscores how well-defined target product profiles can guide diagnostic test development to address pressing clinical needs.